Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 3, 1997, Pages 334-347

  Özdemir, Vural ^a   Naranjo, Claudio A ^a,b   Herrmann, Nathan ^a   Reed, Ken ^a   Sellers, Edward M ^a   Kalow, Werner ^a  

^a University of Toronto ^*

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; CROMOGLYCATE DISODIUM; CYTOCHROME P450 ISOENZYME; PAROXETINE; PERPHENAZINE; PLACEBO; SALBUTAMOL; CYTOCHROME P450 2D6; DOPAMINE RECEPTOR BLOCKING AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SEDATION; ANALYSIS OF VARIANCE; BLOOD; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; MEMORY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; CENTRAL NERVOUS SYSTEM; CYTOCHROME P-450 CYP2D6; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; HUMANS; MEMORY; MIDDLE AGED; PAROXETINE; PERPHENAZINE; PSYCHOMOTOR PERFORMANCE; SEROTONIN UPTAKE INHIBITORS;

EID: 0031225744     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9236(97)90037-0     Document Type: Article

References (66)

1. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-16.
2. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54(suppl):3-15.
3. Naranjo CA, Bremner KE, Özdemir V. Citalopram: a monograph. In: Dollery CT, editor. Therapeutic drugs (supplement 2). Edinburgh: Churchill Livingstone, 1994:47-53.
4. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
5. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993;45: 1211-4.
6. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
7. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
8. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
9. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
10. Dahl-Puustinen ML, Lidén A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78-81.
11. Dahl ML, Ekqvist B, Widen J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991;84:99-100.
12. von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1991;49:234-40.
13. LLerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-7.
14. Huang ML, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, et al. Pharmacokinetics of novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
15. Jerling M, Dahl ML, Åberg-Wistedt A, Liljenberg B, Landell NE, Bertilsson L, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59:423-8.
16. Bertilsson L, Carrillo JA, Dahl ML, LLerena A, Alm C, Bondesson U, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
17. Dahl ML, LLerena A, Bondesson U, Lindström L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994;37:71-4.
18. Bolvig Hansen L, Larsen NE, Vestergard P. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 1981;74:306-9.
19. Bolvig Hansen L, Larsen NE, Gulmann N. Dose-response relationships of perphenazine in the treatment of acute psychosis. Psychopharmacology 1982; 78:112-5.
20. Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schizophr Bull 1991;17:197-216.
21. Dubovsky SL, Thomas M. Psychotic depression: advances in conceptualization and treatment. Hosp Community Psychiatry 1992;43:1189-98.
22. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991;17:649-57.
23. Pollock BG, Mulsant BH, Sweet RA, Rosen J, Altieri LP, Perel JM. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995;31:327-31.
24. Hansen CE, Christensen TR, Elley J, Bolvig Hansen L, Kragh-Sørensen P, Larsen NE, et al. Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 1976;3:915-23.
25. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992;33:521-3.
26. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allan A, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
27. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
28. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
29. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994;34:1222-7.
30. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-12.
31. Ware JE, Sherbourne D. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992;30:473-83.
32. Sellers EM, Naranjo CA, Giles HG, Frecker RC, Beeching M. Intravenous diazepam and oral ethanol interaction. Clin Pharmacol Ther 1980;28:638-45.
33. Wechsler D. A manual for the Wechsler Adult Intelligence Scale. New York: Psychological Corporation, 1955.
34. Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press, 1995.
35. Chouinard G, Ross-Canard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980;7:233.
36. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12:97-104.
37. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
38. Larsen NE, Hansen LB, Knudsen P. Quantitative determination of perphenazine and its dealkylated metabolite using high-performance liquid chromatography. J Chromatogr 1985;341:244-50.
39. Larsen NE, Naestoft J. Determination of perphenazine and its sulphoxide metabolite in human plasma after therapeutic doses by gas chromatography. J Chromatogr 1975;109:259-64.
40. Hartter S, Hermes B, Szegedi A, Hiemke C. Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography. Ther Drug Monit 1994;16:400-6.
41. SPSS 6.1.2 for Windows. Chicago: SPSS Inc.; 1995.
42. Rosner B. Fundamentals of biostatistics. 3rd ed. Belmont: Duxbury Press, Wadsworth Publishing Company, 1990:474-526.
43. Greenblatt DJ, von Moltke LL, Shader RI. The importance of presystemic extraction in clinical psychopharmacology. J Clin Psychopharmacol 1996;16: 417-9.
44. Prueksaritanont T, Dwyer LM, Cribb AE. (+)-Bufuralol 1′-hydroxylation activity in human and rhesus monkey intestine and liver. Biochem Pharmacol 1995;50:1521-5.
45. Kalow W, Tyndale RF. Debrisoquine/sparteine monooxygenase and other P-450s in brain. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992:649-56.
46. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992;72:165-229.
47. Ennis C, Kemp JD, Cox B. Characterization of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem 1981; 36:1515-20.
48. Spampinato U, Esposito E, Samanin R. Serotonin agonists reduce dopamine synthesis in the striatum only when the impulse flow of nigro-striatal neurons is intact. J Neurochem 1985;45:980-2.
49. 2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol 1988;153:89-95.
50. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995;15: 821-9.
51. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979;45:165-75.
52. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. Fluoxetine treatment of depression: clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand 1989;586-96.
53. Caccia S, Fracasso C, Garattini S, Guiso G, Sarati S. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 1992;31:343-7.
54. Baldessarini RJ, Marsh ER, Kula NS. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res 1992;579:152-6.
55. Choo V. Paroxetine and extrapyramidal reactions [abstract]. Lancet 1993;341:624.
56. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995;152:122-5.
57. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
58. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33,227-35.
59. 2-Dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Stand 1994;90:266-8.
60. Gram LF, Overø KF. Drag interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1972;1:463-5.
61. Nelson JC, Jatlow PI. Neuroleptic effect on desipramine steady-state plasma concentrations. Am J Psychiatry 1980;137:1232-4.
62. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition of human liver cytochrome P450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drag Metab Dispos 1985;13:443-8.
63. Von Bahr C, Spina E, Birgersson C, Ericsson Ö, Göransson M, Henthorn T, et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 1985;34: 2501-5.
64. Syvälahti EKG, Lindberg R, Kallio J, De Vocht M. Inhibitory effect of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986;22:89-92.
65. Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 1989;27:272-5.
66. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, et al. Dextromethorphan and mephenytoin phenoryping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992;14:1-8.